BWX Technologies
BWXT
$137.01
-0.14%
BWX Technologies, Inc. is a specialty manufacturer of nuclear components and fuel, operating through a Government Operations segment that builds naval nuclear reactors and fuel for the U.S. Naval Nuclear Propulsion Program and a Commercial Operations segment that supplies steam generators, pressure vessels, reactor components, and spent-fuel storage containers. The company occupies a near-monopoly position in North American large nuclear reactor manufacturing, anchored by sole-source defense contracts that give it a distinct, high-barrier-to-entry identity within the Aerospace & Defense industry. The current investor narrative centers on a multi-year nuclear renaissance — 50% backlog growth in 2025, raised full-year guidance, and capacity expansion through acquisitions — set against a sharp debate over premium valuation and back-half earnings concentration that has driven the stock down roughly a third over the past year despite intact fundamentals. Recent coverage frames BWXT as either the cheapest way to own nuclear growth or a hold until execution proves out, and the divergence between bullish long-term contract visibility and near-term multiple compression is the central tension in the story.…
BWXT
BWX Technologies
$137.01
Related headlines
Investment Opinion: Should I buy BWXT Today?
The synthesized recommendation is Hold, with a bias toward accumulating on stabilization. The core thesis is that BWXT's monopoly-like naval nuclear franchise and 50% backlog growth provide a durable long-term growth engine, but near-term execution risks and a premium valuation warrant caution until the back-half earnings materialize. The analyst consensus rating of 'buy' (mean 1.61) and average target price of $209.44 (52.9% upside) anchor a positive longer-term view, but the recent cautious actions from Wells Fargo (upgraded to Equal Weight) and BNP Paribas (Neutral) suggest limited near-term catalysts.
Supporting evidence includes revenue growth of 18.01% YoY in Q2 2026, a five-quarter streak of sequential revenue increases (32% cumulative), and a 50% backlog expansion in 2025. Profitability is solid with operating margin near 10% and net income growth of 13.5% YoY, while free cash flow TTM of $316.8 million demonstrates cash generation. However, the trailing PE of 48.0x is double the sector average, and the forward PE of 26.2x relies on EPS nearly doubling to $7.71, which is a high bar. The PEG ratio of 2.84 and EV/EBITDA of 31.4x indicate the stock is not cheap on any metric, even after a 34% decline.
Key risks that could invalidate the thesis include a failure to meet back-half earnings guidance, further margin compression, and a breakdown below the 52-week low of $131.60. The rating would upgrade to Buy if the stock stabilizes above $150 and forward EPS estimates are confirmed, or if the PE compresses below 30x on trailing earnings. It would downgrade to Sell if revenue growth decelerates below 10% or if gross margins fall below 20%. Relative to its history and peers, the stock appears overvalued on trailing metrics but fairly valued on forward earnings, suggesting the market is pricing in optimistic growth expectations that must be delivered.
Sign up to view all
BWXT 12-Month Price Forecast
The forward-looking view is balanced: BWXT's monopoly-like naval nuclear franchise and robust backlog provide a strong foundation for multi-year growth, but near-term execution risks and a premium valuation create uncertainty. The stock's sharp decline has brought the forward PE to a more palatable 26.2x, but the trailing multiple remains elevated, and margin compression is a concern. Analyst sentiment is bullish, but the wide target range and cautious institutional actions reflect divergent views on the earnings trajectory. I would upgrade to bullish if the company delivers on back-half earnings and shows margin stabilization, or downgrade to bearish if revenue growth decelerates or the stock breaks below $131.60.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BWX Technologies's 12-month outlook, with a consensus price target around $209.44 and implied upside of +52.9% versus the current price.
Average Target
$209.44
0 analysts
Implied Upside
+52.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$150 - $290
Analyst target range
Coverage is robust with 16 analysts, and the consensus is bullish: the recommendation is "buy" with a mean rating of 1.61 (where 1.0 is a strong buy), and the average target price of $209.44 implies +52.9% upside from the current $137.01. That gap between a "buy" consensus and a stock down 34% over the year is striking and suggests analysts view the selloff as overdone relative to fundamentals, though the recent institutional actions show a more cautious tone — Wells Fargo upgraded to Equal Weight from Underweight in August, BNP Paribas reiterated Neutral in September, and Truist has held at Hold, indicating the bullish consensus is not uniformly shared.
The target range of $150.00 to $290.00 is exceptionally wide — a 93% spread from low to high — signaling high uncertainty about the earnings trajectory and valuation multiple. The high target of $290 assumes multiple expansion back toward prior peaks alongside delivery of the $7.71 consensus EPS and successful commercial nuclear capacity expansion, while the low target of $150 (still 9.5% above the current price) prices in margin compression and a persistent discount multiple. Notably, even the lowest analyst target sits above the current price, implying the Street sees the stock as undervalued at $137, but the clustering of Hold/Neutral ratings alongside Buy ratings suggests conviction is concentrated in the long-term thesis rather than near-term catalysts — investors should expect volatility until the back-half earnings concentration resolves.
Drowning in data?
Find the real signal!
Bulls vs Bears: BWXT Investment Factors
The bear case currently has stronger near-term evidence, given the severe price downtrend, premium valuation, and margin compression, but the bull case rests on a durable monopoly franchise and 50% backlog growth that could drive multi-year earnings expansion. The most important tension is whether BWXT can execute on its back-half earnings guidance to justify the forward PE of 26.2x—if it delivers, the stock could re-rate sharply; if it stumbles, further multiple compression is likely. Analyst consensus leans bullish with a $209.44 average target, but the wide target range ($150-$290) and mixed institutional actions reflect high uncertainty. The stock's low beta and defensive characteristics may limit downside, but the lack of a technical bottom suggests patience is warranted until a catalyst emerges.
Bullish
- Monopoly in Naval Nuclear Franchise: BWXT holds sole-source contracts for the U.S. Naval Nuclear Propulsion Program, contributing $577.9 million (64% of Q2 2026 revenue) from Government Operations. This near-monopoly position creates extremely high barriers to entry and provides multi-year revenue visibility that few defense peers can match.
- Strong Revenue Growth and Backlog: Q2 2026 revenue grew 18.01% YoY to $901.6 million, extending a five-quarter streak of sequential increases from $682.3 million in Q1 2025 to $901.6 million—a 32% rise. Backlog expanded 50% in 2025, signaling robust demand for nuclear components and fuel.
- Analyst Consensus Sees 53% Upside: With 16 analysts covering the stock, the consensus rating is 'buy' (mean 1.61) and the average target price of $209.44 implies +52.9% upside from $137.01. Even the lowest target of $150 is 9.5% above the current price, suggesting the Street views the selloff as overdone.
- Forward Valuation More Reasonable: While trailing PE is elevated at 48.0x, the forward PE of 26.2x is much closer to sector norms and reflects expected EPS growth to $7.71. The PEG ratio of 2.84, though not cheap, is more palatable given the 18% revenue growth and 50% backlog expansion.
Bearish
- Premium Valuation vs. Peers and History: Trailing PE of 48.0x is roughly double the Aerospace & Defense sector average in the low-to-mid 20s, and EV/EBITDA of 31.4x is rich. The stock's historical PE range of 9.4x to 51.6x places the current multiple near the top, leaving little room for error.
- Severe Price Downtrend and Weak Technicals: The stock is down 34.45% over the past year and 41.89% over six months, trading just 4.1% above its 52-week low of $131.60. The max drawdown of -43.65% and relative strength of -49.98% vs. SPY over one year indicate persistent selling pressure and lack of investor confidence.
- Margin Compression and Earnings Quality: Gross margin declined from 25.05% in Q2 2025 to 22.44% in Q2 2026, likely due to mix shift toward lower-margin commercial work and capacity expansion costs. Net margin of 9.87% is thin for a premium-valued stock, and ROE of 26.75% is flattered by a 3.3x equity multiplier.
- Elevated Leverage and Cash Flow Constraints: Debt-to-equity of 1.635 is high for an industrial, and free cash flow TTM of $316.8 million yields only ~2.0% of market cap. Heavy capex ($41.4 million in Q2 alone) consumes a large share of operating cash, limiting financial flexibility.
BWXT Technical Analysis
BWXT is in a pronounced, sustained downtrend, with the 1-year price change of -34.45% and a 6-month decline of -41.89% reflecting a persistent series of lower highs and lower lows. At $137.01, the stock sits just 4.1% above its 52-week low of $131.60 and 43.3% below its 52-week high of $241.82 — trading at roughly 23.5% of its 52-week range, a positioning that signals capitulation-like weakness rather than momentum, and raises the question of whether this is a value opportunity or a falling knife given the absence of any base-building. The max drawdown of -43.65% confirms the severity of the de-rating from the April 2026 peak near $228.24.
Short-term momentum remains negative but is decelerating in its rate of decline: the 1-month change of -5.94% and 3-month change of -19.96% are both worse than the broader market, with relative strength of -7.16% versus SPY over one month and -22.65% over three months. The 1-month decline is materially smaller than the 3-month and 6-month declines, suggesting the selling pressure is losing intensity even as the trend has not reversed — a potential early-stage stabilization rather than a confirmed bottom. The stock's bounce from $134.35 on September 28 to $145.70 on October 6 (+8.4% in six sessions) followed by a fade back to $137.01 shows buyers defending the low-$130s but lacking conviction to sustain rallies, consistent with a market awaiting a fundamental catalyst.
Key technical levels are well defined: support rests at the 52-week low of $131.60, with the October 14 close of $134.44 marking the most recent test of that zone, while resistance sits at the 52-week high of $241.82 — a level so distant that intermediate resistance around $150 (the low end of analyst targets) is the more actionable hurdle. A breakdown below $131.60 would signal a fresh leg lower and likely trigger momentum-driven selling, whereas a reclaim of $150 would be the first evidence of trend repair. The beta of 0.738 indicates the stock is roughly 26% less volatile than the market, which is unusual for a name in a 43% drawdown and implies the decline has been driven by stock-specific de-rating rather than broad market beta — position sizing should account for idiosyncratic rather than systematic risk.
Beta
0.74
0.74x market volatility
Max Drawdown
-43.6%
Largest decline past year
52-Week Range
$132-$242
Price range past year
Annual Return
-34.4%
Cumulative gain past year
| Period | BWXT Return | S&P 500 |
|---|---|---|
| 1m | -5.9% | +0.2% |
| 3m | -20.0% | +2.9% |
| 6m | -41.9% | +8.4% |
| 1y | -34.4% | +14.9% |
| ytd | -24.7% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BWXT Fundamental Analysis
Revenue is growing at a healthy clip rather than decelerating: Q2 2026 revenue of $901.6 million rose 18.01% year-over-year versus $764.0 million in Q2 2025, extending a string of sequential increases from $861.1 million in Q1 2026 and $885.8 million in Q4 2025. The multi-quarter trajectory is clearly upward — quarterly revenue has climbed from $682.3 million in Q1 2025 to $901.6 million in Q2 2026, a 32% increase over five quarters — and segment data shows Government Operations contributing $577.9 million (64% of the total) versus $283.6 million from Commercial Operations, confirming that the naval nuclear franchise is the primary growth engine with commercial nuclear providing incremental upside. This growth profile, reinforced by 50% backlog expansion, supports a durable multi-year investment case even as the stock has de-rated.
Profitability is solid and improving at the operating line: Q2 2026 net income of $89.0 million on a 9.87% net margin and 22.44% gross margin compares favorably to Q2 2025's $78.4 million net income and 25.05% gross margin, showing margin mix compression at the gross level but net income growth of 13.5% year-over-year. Operating margin has been remarkably stable near 10% (9.97% in Q2 2026, 9.97% in Q1 2026, 8.08% in Q4 2025), and the trailing operating margin of 10.11% with a net margin of 10.31% is consistent with a defense contractor's typical mid-single-to-low-double-digit profitability. The gross margin decline from 25.05% to 22.44% year-over-year warrants monitoring — it likely reflects mix shift toward lower-margin commercial work and capacity expansion costs — but EBITDA of $121.2 million (13.45% margin) confirms the business remains comfortably profitable.
Balance sheet and cash flow are adequate but leverage is meaningful: debt-to-equity of 1.635 is elevated for an industrial, though the current ratio of 2.32 and interest coverage of 17.0x (per historical ratios) indicate ample liquidity and debt-service capacity. Free cash flow TTM of $316.8 million against a $15.8 billion market cap yields only about 2.0%, and the Q2 2026 FCF of $115.0 million (operating cash flow $156.4 million less capex $41.4 million) shows the business does generate cash, but heavy capex — $41.4 million in Q2 alone and $70.2 million in Q4 2025 — consumes a large share of operating cash. ROE of 26.75% is strong on a reported basis, though it is flattered by the 3.3x equity multiplier; the company funds growth internally but with limited cushion, and the 0.58% dividend yield with a 28% payout ratio leaves modest room for shareholder returns.
Quarterly Revenue
$901625000.0B
2026-06
Revenue YoY Growth
+18.0%
YoY Comparison
Gross Margin
22.4%
Latest Quarter
Free Cash Flow
$316762000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BWXT Overvalued?
Because net income is positive ($89.0 million in Q2 2026), the PE ratio is the appropriate primary metric: the trailing PE of 48.0x against a forward PE of 26.2x implies the market expects earnings to nearly double, consistent with consensus EPS of $7.71 versus trailing EPS of roughly $2.85 (annualized from the $0.97 quarterly figure). That 45% compression in the multiple on forward earnings reflects both genuine growth expectations and the sharp price decline — the stock has de-rated even as estimates have held, which is the crux of the valuation debate. The PEG ratio of 2.84 and EV/EBITDA of 31.4x confirm the stock is not cheap on any absolute measure despite the drawdown.
Against the Aerospace & Defense industry, BWXT trades at a substantial premium: the trailing PE of 48.0x versus a sector average typically in the low-to-mid 20s represents roughly a 100% premium, and the PS ratio of 4.95x and EV/Sales of 3.98x are also rich for a defense contractor. The premium is partially justified by BWXT's sole-source naval reactor monopoly, 50% backlog growth, and exposure to the secular nuclear buildout — attributes most defense peers lack — but the 12.8x price-to-book and 33.0x price-to-cash-flow suggest the market is paying for growth that must be delivered. The forward PE of 26.2x is far more reasonable and closer to sector norms, implying the premium is largely a function of depressed trailing earnings rather than an inherently expensive forward multiple.
Historically, BWXT's PE has ranged from roughly 9.4x (Q4 2021) to 51.6x (Q1 2026), with the current 48.0x trailing multiple near the top of that band even after the 34% price decline — a function of the earnings base rather than the price. The PS ratio of 4.95x, however, is near the low end of its historical range (which peaked above 21x in Q1 2026 and troughed near 7.1x in 2022), and the PB of 12.8x is near the high end of its 6.5x–14.6x range. The mixed picture — expensive on earnings and book, cheap on sales relative to its own history — suggests the market has priced in optimistic long-term expectations that are now being tested, and the stock's historical tendency to trade at 25–35x earnings implies further downside if growth disappoints.
PE
48.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~52x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
31.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are centered on elevated leverage and margin pressure. Debt-to-equity of 1.635 is high for an industrial, and although interest coverage of 17.0x is comfortable, the $15.8 billion market cap supports only a 2.0% free cash flow yield, limiting financial flexibility. Gross margin has compressed from 25.05% to 22.44% year-over-year, likely due to mix shift toward lower-margin commercial work and capacity expansion costs, and net margin of 9.87% leaves little cushion for operational missteps. Revenue concentration in Government Operations (64% of Q2 2026 revenue) ties the company's fortunes to defense budgets and naval procurement cycles, while the commercial segment's growth requires successful integration of recent acquisitions.
Market and competitive risks include valuation compression and sector rotation. The trailing PE of 48.0x is roughly double the Aerospace & Defense sector average, and EV/EBITDA of 31.4x is rich, leaving the stock vulnerable to multiple contraction if growth disappoints or interest rates remain elevated. Beta of 0.738 suggests lower market correlation, but the stock has underperformed SPY by 49.98% over one year, indicating idiosyncratic de-rating. Competitive threats are limited by BWXT's near-monopoly in naval nuclear reactors, but the commercial nuclear segment faces competition from other suppliers and potential disruption from small modular reactor (SMR) technologies. Regulatory headwinds, such as changes in defense spending or nuclear safety regulations, could also impact demand.
The worst-case scenario involves a breakdown below the 52-week low of $131.60, triggered by a significant earnings miss or guidance cut due to execution issues in the back-half ramp-up. From the current price of $137.01, a decline to the 52-week low represents a 3.9% loss, but a more severe de-rating to the historical low-end PE of 25-35x on trailing earnings could imply a price near $100, a 27% downside. The analyst low target of $150 is above the current price, but if sentiment sours, the stock could test the $120-$130 range, especially if the forward EPS estimate of $7.71 is not met. The max drawdown of -43.65% from the April 2026 peak illustrates the potential for sharp declines in adverse scenarios.
FAQ
The key risks for BWXT are ranked as follows: 1) Execution risk—the forward PE of 26.2x assumes EPS doubles to $7.71, and any miss could cause a sharp decline; 2) Valuation risk—trailing PE of 48.0x is double the sector average, leaving room for multiple compression; 3) Margin risk—gross margin has compressed from 25.05% to 22.44% YoY, and further pressure could hurt profitability; 4) Leverage risk—debt-to-equity of 1.635 is high, and free cash flow yield is only 2.0%, limiting flexibility. Additionally, the stock is in a severe downtrend, down 34.45% over one year, and a break below $131.60 could trigger momentum selling. These risks are significant but partially mitigated by the company's monopoly-like naval nuclear franchise and 50% backlog growth.
The 12-month forecast for BWXT includes three scenarios: Bull case (25% probability) with a target range of $240-$290, assuming successful execution and multiple expansion; Base case (50% probability) with a target range of $180-$220, assuming consensus EPS of $7.71 is met and the stock re-rates modestly; Bear case (25% probability) with a target range of $130-$150, assuming earnings miss and a break below the 52-week low. The base case is most likely, driven by steady backlog conversion and gradual margin improvement, but the wide range reflects high uncertainty. Key assumptions include revenue growth of ~18% to $5.43 billion and stable defense spending. The analyst average target of $209.44 aligns with the base case.
BWXT appears overvalued on trailing metrics but fairly valued on forward earnings. The trailing PE of 48.0x is roughly double the Aerospace & Defense sector average, and EV/EBITDA of 31.4x is rich. However, the forward PE of 26.2x is much closer to sector norms, implying the market expects EPS to nearly double to $7.71. The PS ratio of 4.95x is near the low end of its historical range, while the PB of 12.8x is near the high end, presenting a mixed picture. Relative to its own history, the stock has traded at 25-35x earnings, so the current forward multiple is within range. The market is pricing in optimistic growth expectations that must be delivered; if they are, the stock could be undervalued, but any shortfall could lead to further de-rating.
BWXT presents a compelling long-term buy for investors who believe in the nuclear renaissance and can tolerate near-term volatility. The stock trades at $137.01, a 52.9% discount to the analyst average target of $209.44, and the forward PE of 26.2x is reasonable given 18% revenue growth and a 50% backlog expansion. However, the trailing PE of 48.0x is double the sector average, and margin compression (gross margin down from 25.05% to 22.44% YoY) poses a risk. The biggest downside risk is a breakdown below the 52-week low of $131.60, which could trigger further selling. For risk-tolerant investors with a multi-year horizon, the risk/reward is favorable, but conservative investors may want to wait for execution proof.
BWXT is more suitable for long-term investment (minimum 2-3 years) given its multi-year backlog visibility and the secular nuclear growth theme. The stock's beta of 0.738 suggests lower volatility than the market, but it has experienced a 43.65% max drawdown, indicating significant idiosyncratic risk. The dividend yield is low at 0.58%, so returns will depend on capital appreciation. Near-term, the stock is in a downtrend and lacks a catalyst, making it less attractive for short-term trading. Earnings visibility is improving with the 50% backlog growth, but execution risk remains. Investors should be prepared for volatility and consider accumulating on stabilization above $150 or a confirmed bottom near $131.60.
